Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
200 | 200 | 14,246,100 | 1,631 | A method of estimating a likelihood of developing a disease is disclosed. The method comprises obtaining a set of gene sequences corresponding to the disease and a DNA sequence of a subject. The method further comprises, for each gene sequence of the set, searching over the DNA sequence for reoccurrences of the gene se... | 1. A method of estimating a likelihood of developing a disease, the method comprising performing the following operations on a data processor:
obtaining a set of gene sequences corresponding to the disease; obtaining a DNA sequence of a subject; for each gene sequence of said set, searching over said DNA sequence for r... | A method of estimating a likelihood of developing a disease is disclosed. The method comprises obtaining a set of gene sequences corresponding to the disease and a DNA sequence of a subject. The method further comprises, for each gene sequence of the set, searching over the DNA sequence for reoccurrences of the gene se... | 1,600 |
201 | 201 | 15,270,327 | 1,611 | The present disclosure relates to an oral, extended release pill containing a drug which is homogenously spread throughout a matrix. The pill can be prepared using a hot melt extrusion process and a forming unit. The formed pill meets regulatory guidelines for extended release formulations and can be abuse deterrent to... | 1. An oral, extended release pill comprising a drug and
(i) 30 wt % to 50 wt % of polyethylene oxide having an average molecular weight between 50K Daltons and 150K Daltons; (ii) 8 wt % to 60 wt % of a controlled release agent; (iii) 0.2 wt % to 20 wt % polyethylene glycol;
wherein the drug has an extended release pro... | The present disclosure relates to an oral, extended release pill containing a drug which is homogenously spread throughout a matrix. The pill can be prepared using a hot melt extrusion process and a forming unit. The formed pill meets regulatory guidelines for extended release formulations and can be abuse deterrent to... | 1,600 |
202 | 202 | 14,474,267 | 1,636 | Disclosed are embodiments of methods, apparatus, systems, compositions, and articles of manufacture relating to identifying the source of bioparticles, such as bioparticles shed by an organism. In embodiments, a method may include collecting a sample of bioparticles from the environment, selecting from that sample the ... | 1. A method for identifying a biological source, the method comprising:
collecting from the environment a plurality of bioparticles shed by a biological source organism; selecting one or more information-rich bioparticles from the plurality of bioparticles; restricting the movement of the one or more information-rich b... | Disclosed are embodiments of methods, apparatus, systems, compositions, and articles of manufacture relating to identifying the source of bioparticles, such as bioparticles shed by an organism. In embodiments, a method may include collecting a sample of bioparticles from the environment, selecting from that sample the ... | 1,600 |
203 | 203 | 14,499,191 | 1,627 | The invention relates generally to ephedrine or pseudoephedrine compositions containing biocompatible organoleptic (food flavoring) excipients that would prevent the illicit manufacture of methamphetamine from ephedrine or pseudoephedrine. | 1. A pharmaceutically acceptable composition, comprising
(a) ephedrine or pseudoephedrine, and (b) a suitable amount of an organoleptic agent, wherein the organoleptic agent is effective in inhibiting the conversion of the ephedrine or pseudoephedrine to methamphetamine. 2. The composition of claim 1 wherein
(a) the ep... | The invention relates generally to ephedrine or pseudoephedrine compositions containing biocompatible organoleptic (food flavoring) excipients that would prevent the illicit manufacture of methamphetamine from ephedrine or pseudoephedrine.1. A pharmaceutically acceptable composition, comprising
(a) ephedrine or pseudoe... | 1,600 |
204 | 204 | 15,289,566 | 1,616 | Methods of improving the growth of a plant by applying a plant growth effective amount of a plant growth composition that includes a hydrated aluminum magnesium silicate and at least one dispersant selected from the group consisting of a sucrose ester, a lignosulfonate, an alkylpolyglycoside, a naphthalenesulfonic acid... | 1. A method of improving the growth of a plant comprising applying a plant growth effective amount of a plant growth composition comprising a hydrated aluminum-magnesium silicate and at least one dispersant selected from the group consisting of a sucrose ester, a limosulfonate, an alkylpolyglycoside, a naphthalenesulfo... | Methods of improving the growth of a plant by applying a plant growth effective amount of a plant growth composition that includes a hydrated aluminum magnesium silicate and at least one dispersant selected from the group consisting of a sucrose ester, a lignosulfonate, an alkylpolyglycoside, a naphthalenesulfonic acid... | 1,600 |
205 | 205 | 15,049,946 | 1,639 | The hemitartrate salt of a compound represented by the following structural formula:
(Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (... | 1-93. (canceled) 94. A method of treating a subject with Gaucher disease who has been assessed as being a poor, intermediate or extensive P450 metabolizer, the method comprising administering to the subject a compound represented by the following structural formula
or a pharmaceutically acceptable salt thereo... | The hemitartrate salt of a compound represented by the following structural formula:
(Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (... | 1,600 |
206 | 206 | 15,337,410 | 1,617 | Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such i... | 1. A method for preventing intestinal polyps or intestinal cancer in a patient comprising administering an effective amount of a composition comprising rapamycin or an analog thereof to a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. 2. The method of claim 1, wh... | Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such i... | 1,600 |
207 | 207 | 15,082,658 | 1,651 | The current technology is related to methods for rapidly determining the metabolic baseline and potential of living cells. Embodiments relate to measuring the activity of each of the two major energy-generating pathways within the cell: mitochondrial respiration and glycolysis, first under baseline conditions, and agai... | 1. A method of determining a metabolic potential of a cell sample, the method comprising the steps of:
measuring an initial oxygen consumption rate and an initial extracellular acidification rate of the cell sample; thereafter, simultaneously administering to the cell sample a mitochondrial uncoupling agent and an ATP ... | The current technology is related to methods for rapidly determining the metabolic baseline and potential of living cells. Embodiments relate to measuring the activity of each of the two major energy-generating pathways within the cell: mitochondrial respiration and glycolysis, first under baseline conditions, and agai... | 1,600 |
208 | 208 | 14,613,420 | 1,613 | Products and methods are disclosed for reducing the production of unwanted odors from the pudendum. | 1. A product for application to the pudendum of a user to reduce fishy odor, the product comprising at least 1% by weight of mandelic acid in a viscous lipophilic carrier having a non-zero yield stress, the product being physically associated with indicia specifying that the product should be applied to the entire pude... | Products and methods are disclosed for reducing the production of unwanted odors from the pudendum.1. A product for application to the pudendum of a user to reduce fishy odor, the product comprising at least 1% by weight of mandelic acid in a viscous lipophilic carrier having a non-zero yield stress, the product being ... | 1,600 |
209 | 209 | 14,283,073 | 1,611 | A waterborne topical composition is designed specifically to address the treatment of acne vulgaris, rosacea, seborrheic dermatitis and other skin conditions. One composition contains effective amounts of essential components azelaic acid, niacinamide, and glycerin to create a rapidly penetrating and non-irritating com... | 1. A waterborne topical composition for the treatment of acne vulgaris, rosacea, seborrheic dermatitis or other skin conditions comprising effective amounts of azelaic acid, niacinamide, and wherein the composition demonstrates a penetration rate of at least 5% active ingredient/hr, within 2.5 hours of application to h... | A waterborne topical composition is designed specifically to address the treatment of acne vulgaris, rosacea, seborrheic dermatitis and other skin conditions. One composition contains effective amounts of essential components azelaic acid, niacinamide, and glycerin to create a rapidly penetrating and non-irritating com... | 1,600 |
210 | 210 | 14,692,422 | 1,633 | The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding th... | 1. A method for delivering a drug across the blood-central nervous system (CNS) barrier, comprising administering to a subject in need thereof an effective amount of a drug-encapsulating nanocontainer according to claim 21 or claim 22 such that the drug
(a) is delivered across the blood-CNS barrier,
(b) accumulates sel... | The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding th... | 1,600 |
211 | 211 | 13,772,796 | 1,641 | The present invention provides methods, kits, compositions, and devices for detecting Anti-Mullerian hormone (AMH) in whole blood samples. In certain embodiments, the methods, kits, compositions, and devices employ immunoassays that generate a colorimetric or fluorescent signal (e.g., using antibodies conjugated to gol... | 1. A method of determining the approximate concentration of Anti-Mullerian hormone (AMH) in a whole blood sample comprising:
a) contacting a whole blood sample from a subject with first antibodies specific for AMH under conditions such that a signal is generated that is proportional to the approximate concentration of ... | The present invention provides methods, kits, compositions, and devices for detecting Anti-Mullerian hormone (AMH) in whole blood samples. In certain embodiments, the methods, kits, compositions, and devices employ immunoassays that generate a colorimetric or fluorescent signal (e.g., using antibodies conjugated to gol... | 1,600 |
212 | 212 | 13,147,905 | 1,643 | A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided.
An object of the present invention can be solved by being brought into contact a lectin having an affinity for β-N-acetylgalactosamine residues and/or a lectin having ... | 1. A method for analyzing PSA, characterized in that a lectin having an affinity for β-N-acetylgalactosamine residues is brought into contact with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. 2. The method for analyzing PSA according to claim 1, comprising the steps... | A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided.
An object of the present invention can be solved by being brought into contact a lectin having an affinity for β-N-acetylgalactosamine residues and/or a lectin having ... | 1,600 |
213 | 213 | 14,139,519 | 1,645 | A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a met... | 1-8. (canceled) 9. A lyophilized or vacuum dried pharmaceutical composition comprising:
(a) a botulinum toxin, wherein the botulinum toxin is not stabilized by a protein excipient, (b) polyvinylpyrrolidone, and (c) a disaccharide, wherein the potency of the botulinum toxin after reconstitution is at least 40% of the th... | A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin, wherein the Clostridial toxin present in the pharmaceutical composition is stabilized by a non-protein excipient such as a polyvinylpyrrolidone, a disaccharides, a trisaccharide, a polysaccharide, an alcohol, a met... | 1,600 |
214 | 214 | 10,337,661 | 1,627 | The present invention is a cosmetic or dermatological preparation or method of applying a cosmetic or dermatological preparation for the treatment or prophylaxis of skin damage or a skin condition, wherein the preparation includes creatine or a creatine derivative. The use of creatine or creatine derivatives in the cos... | 1. A method for the treatment or prophylaxis of the symptoms of skin damage or a skin condition, comprising applying a cosmetic or dermatological preparation comprising one or more compounds selected from the group consisting of creatine and creatine derivatives to the skin damage or skin condition. 2. The method as cl... | The present invention is a cosmetic or dermatological preparation or method of applying a cosmetic or dermatological preparation for the treatment or prophylaxis of skin damage or a skin condition, wherein the preparation includes creatine or a creatine derivative. The use of creatine or creatine derivatives in the cos... | 1,600 |
215 | 215 | 14,772,961 | 1,611 | Suggested is a cosmetic composition, comprising (a) at least one acetophenone derivative or a cosmetically or pharmaceutically acceptable salt thereof in a working amount of from 0.1 to 0.5 b.w.—calculated on the total composition, (b) at least one oil body or wax, and/or (c) at least one emulsifier and optionally (d) ... | 1. A cosmetic composition, comprising
(a) at least one acetophenone derivative of formula (I)
in which
R1 stands for hydrogen or methyl, and
R2 stands for hydrogen, hydroxyl or a —OCH3 group,
or a cosmetically or pharmaceutically acceptable salt thereof in a working amount of from 0.1 to 0.5% b.w.—calculate... | Suggested is a cosmetic composition, comprising (a) at least one acetophenone derivative or a cosmetically or pharmaceutically acceptable salt thereof in a working amount of from 0.1 to 0.5 b.w.—calculated on the total composition, (b) at least one oil body or wax, and/or (c) at least one emulsifier and optionally (d) ... | 1,600 |
216 | 216 | 12,866,786 | 1,612 | This invention relates to methods of treating early enamel lesions comprising applying an effective amount of a basic amino acid in free or salt form, together with fluoride to a patient in need thereof. | 1. A method of treating early enamel caries comprising:
applying an effective amount of a dentifrice composition to the oral cavity, the dentifrice composition having a base formulation comprising calcium carbonate, the dentifrice composition further comprising
arginine, in free or salt form, and
an effective amount of... | This invention relates to methods of treating early enamel lesions comprising applying an effective amount of a basic amino acid in free or salt form, together with fluoride to a patient in need thereof.1. A method of treating early enamel caries comprising:
applying an effective amount of a dentifrice composition to t... | 1,600 |
217 | 217 | 15,204,826 | 1,617 | The present invention relates to a methods of preparing active compounds complexed with lipids using aqueous systems that are free of organic solvents, and methods of using the complexes, e.g., in treating a disease in a subject. In some embodiments, the present invention comprises a composition comprising a complex co... | 1. A method of treating a disease in a subject, comprising:
a) using an aqueous system to prepare a composition comprising a complex, said complex comprising at least one active compound and at least one lipid; and b) administering said composition to a subject. 2. The method of claim 1, wherein said complex comprises ... | The present invention relates to a methods of preparing active compounds complexed with lipids using aqueous systems that are free of organic solvents, and methods of using the complexes, e.g., in treating a disease in a subject. In some embodiments, the present invention comprises a composition comprising a complex co... | 1,600 |
218 | 218 | 14,354,080 | 1,623 | The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a topoisomerase II-inhibiting amount of a long-acting topoisomerase II inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor. | 1. A method comprising the steps of: (a) administering to a patient a topoisomerase II-inhibiting amount of a long-acting topoisomerase II inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor. 2. The method of claim 1, wherein the patient is suff... | The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a topoisomerase II-inhibiting amount of a long-acting topoisomerase II inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.1. A method ... | 1,600 |
219 | 219 | 13,427,582 | 1,645 | Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients. | 1. An animal-protein free, solid-form Clostridial toxin pharmaceutical composition comprising a Clostridial toxin active ingredient, an effective amount of lactose, an effective amount of sucrose, and an effective amount of sodium chloride; and
wherein after storage for one year the pharmaceutical composition exhibits ... | Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.1. An animal-protein free, solid-form Clostridial toxin pharmaceutical composition comprising a Clostridial toxin active ingredient, an effective amount of lactose, ... | 1,600 |
220 | 220 | 13,800,495 | 1,641 | The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixtu... | 1. A method of isolating a target from a sample, the method comprising:
a) forming a mixture comprising a sample, an antibody-linked immuno-sedimentation agent and red blood cells, wherein the antibody-linked immuno-sedimentation agent comprises
1) at least one sedimentation agent and
2) at least one antibody linked to... | The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixtu... | 1,600 |
221 | 221 | 14,878,561 | 1,656 | The disclosure describes methods for the purification of protein-enriched extracts to provide concentrates and isolates and methods for incorporation of such materials into products. The purification methods are adapted for removal of one or more of ash, metal salts, alkaloids, particulates, heavy metals, and other imp... | 1.-27. (canceled) 28. A method for modifying the sensory characteristics of a protein-enriched material, the method comprising:
a) receiving a plant-derived, protein-enriched material comprising RuBisCO, F2 fraction proteins, or a combination thereof, wherein the plant-derived, protein-enriched material exhibits an ini... | The disclosure describes methods for the purification of protein-enriched extracts to provide concentrates and isolates and methods for incorporation of such materials into products. The purification methods are adapted for removal of one or more of ash, metal salts, alkaloids, particulates, heavy metals, and other imp... | 1,600 |
222 | 222 | 15,072,965 | 1,612 | Embodiments herein related to multi-component packaged food products which have been thermally processed to achieve commercial sterility in a package, including at least a first component and a second component in contact with (e.g., immersed in) the first component, wherein said first component is comprised of a subst... | 1. A multi-component packaged food product which has been thermally processed to achieve commercial sterility in a package, including at least a first component and a second component in contact with the first component, wherein said first component is a substantially water-based, liquid, pasty or gelled food, and wher... | Embodiments herein related to multi-component packaged food products which have been thermally processed to achieve commercial sterility in a package, including at least a first component and a second component in contact with (e.g., immersed in) the first component, wherein said first component is comprised of a subst... | 1,600 |
223 | 223 | 14,336,455 | 1,633 | A mycological biopolymer product consisting entirely of fungal mycelium is made by inoculating a nutritive substrate with a selected fungus in a sealed environment except for a void space, which space is subsequently filled with a network of undifferentiated fungal mycelium. The environmental conditions for producing t... | 1. A mycological biopolymer material characterized in being free of any stipe, cap, or spores. 2. A process of growing a mycological biopolymer material comprising the steps of
providing a tool defining a cavity therein with an opening into said cavity; packing said cavity of the tool with nutritive substrate and a fun... | A mycological biopolymer product consisting entirely of fungal mycelium is made by inoculating a nutritive substrate with a selected fungus in a sealed environment except for a void space, which space is subsequently filled with a network of undifferentiated fungal mycelium. The environmental conditions for producing t... | 1,600 |
224 | 224 | 13,813,705 | 1,663 | The invention relates to endonucleases cleaving DNA target sequences from algae genomes, to appropriate vectors encoding such endonucleases, to cells or to algae modified by such vectors and to the use of these endonucleases and products derived therefrom for targeted genomic engineering in algae. | 1-15. (canceled) 16. A method for targeted genomic engineering in an algal cell comprising introducing an endonuclease into the algal cell to induce a double-stranded cleavage at a site of interest in the genome of the algal cell. 17. The method of claim 16, comprising:
providing an endonuclease capable of inducing a d... | The invention relates to endonucleases cleaving DNA target sequences from algae genomes, to appropriate vectors encoding such endonucleases, to cells or to algae modified by such vectors and to the use of these endonucleases and products derived therefrom for targeted genomic engineering in algae.1-15. (canceled) 16. A... | 1,600 |
225 | 225 | 14,385,331 | 1,633 | The disclosure provides non-human optogenetic animal models of depression. Specifically, non-human animals each expresses a light-responsive opsin in a neuron of the animal are provided. The animal models are useful for identifying agents and targets of therapeutic strategies for treatment of depression. Examples of us... | 1. A method for identifying a candidate agent treating depression in an individual, comprising:
contacting a rodent that expresses an active optogenetic inhibitor of neuronal activity in ventral tegmental area (VTA) dopaminergic neurons with a test agent, and determining the effect of the test agent on a behavior of th... | The disclosure provides non-human optogenetic animal models of depression. Specifically, non-human animals each expresses a light-responsive opsin in a neuron of the animal are provided. The animal models are useful for identifying agents and targets of therapeutic strategies for treatment of depression. Examples of us... | 1,600 |
226 | 226 | 13,639,752 | 1,612 | The invention relates to novel pharmaceutical compositions highly dosed with biotin, as well as to the use thereof in treating visual impairments which are related, in particular, to optic atrophy. | 1. A composition for oral administration, containing more than 20 mg of biotin per unit dose. 2. The composition as claimed in claim 1, characterized in that it is in the form of gel capsules, tablets (optionally film-coated), lozenges or pills. 3. The composition as claimed in claim 1, characterized in that it contain... | The invention relates to novel pharmaceutical compositions highly dosed with biotin, as well as to the use thereof in treating visual impairments which are related, in particular, to optic atrophy.1. A composition for oral administration, containing more than 20 mg of biotin per unit dose. 2. The composition as claimed... | 1,600 |
227 | 227 | 13,656,413 | 1,613 | Pharmaceutical preparations, compositions, systems, and devices including medical devices and diagnostic or therapeutic agents, and methods to treat disease by modification of local tissue environment to modulate the therapeutic index of locally or systemically delivered therapeutic or diagnostic agents. Improved abili... | 1. A composition comprising a guanidine with pH>8. 2. The composition of claim 1, wherein the guanidine is guanethidine. 3. The composition of claim 2, wherein the guanethidine includes monosulfate, hemisulfate in a solution configured for denervation, or hemisulfate in a solution suitable for denervation. 4. (canceled... | Pharmaceutical preparations, compositions, systems, and devices including medical devices and diagnostic or therapeutic agents, and methods to treat disease by modification of local tissue environment to modulate the therapeutic index of locally or systemically delivered therapeutic or diagnostic agents. Improved abili... | 1,600 |
228 | 228 | 15,425,713 | 1,613 | A skin care composition in the form of a water-in-oil, high internal phase emulsion that provides an improved sensory experience when applied to keratinous tissue. The thick, creamy consistency of the emulsion provides a moisturization signal to the consumer, but the shear thinning behavior of the high internal phase e... | 1. A personal care composition in the form of a water-in-oil, high internal phase emulsion, comprising:
a. more than about 74%, by volume, of an internal aqueous phase; b. about 0.01% to about 3%, by weight, of a superabsorbent polymer (SAP) in the aqueous phase; and c. less than about 26%, by volume, of a continuous o... | A skin care composition in the form of a water-in-oil, high internal phase emulsion that provides an improved sensory experience when applied to keratinous tissue. The thick, creamy consistency of the emulsion provides a moisturization signal to the consumer, but the shear thinning behavior of the high internal phase e... | 1,600 |
229 | 229 | 14,162,181 | 1,629 | Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an... | 1. A method of treating non-alcoholic steatohepatitis comprising:
administering a drug comprising an effective amount of 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same to a patient in need thereof. 2. The ... | Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an... | 1,600 |
230 | 230 | 13,618,803 | 1,631 | A system and method whereby acoustic signals can be classified and identified as to nature and location of the original signal. The system and method determine from an arbitrary set of signals a signature or other characterizing feature and distinguish signals associated with a plurality of conditions by means of dicti... | 1. A system for extracting, detecting, classifying, discriminating, localizing, and processing signals comprising:
a. at least one transducer device operable to collect a plurality of signals; b. a processing device coupled to said transducer device, said processing device executing instructions for decomposing the sig... | A system and method whereby acoustic signals can be classified and identified as to nature and location of the original signal. The system and method determine from an arbitrary set of signals a signature or other characterizing feature and distinguish signals associated with a plurality of conditions by means of dicti... | 1,600 |
231 | 231 | 14,929,111 | 1,615 | Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula:
wherein: R 1 and R 9 are independently selected from: —H; C 1-4 alkyl; C 2-4 alkenyl; and halogenated C 1-4 alkyl; each of ... | 1. A method of preparing a 3,7-diamino-10H-phenothiazine (DAPTZ) compound of formula (1):
wherein:
each of R1 and R9 is independently selected from: —H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl;
each of R3NA and R3NB is independently selected from: —H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alky... | Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula:
wherein: R 1 and R 9 are independently selected from: —H; C 1-4 alkyl; C 2-4 alkenyl; and halogenated C 1-4 alkyl; each of ... | 1,600 |
232 | 232 | 14,931,316 | 1,613 | The present invention relates to a nail composition containing at least one adhesive agent, at least one primary film former and at least one plasticizer. | 1. A nail composition comprising:
at least one adhesive agent, wherein the at least one adhesive agent is selected from the group consisting of radical or polycondensate synthetic polymers, polymers of natural origin, and mixtures thereof; at least one primary film former, wherein the at least one primary film former i... | The present invention relates to a nail composition containing at least one adhesive agent, at least one primary film former and at least one plasticizer.1. A nail composition comprising:
at least one adhesive agent, wherein the at least one adhesive agent is selected from the group consisting of radical or polycondens... | 1,600 |
233 | 233 | 15,363,317 | 1,617 | The present invention relates to a simple, robust and effective process for preparing a dry powder inhalation formulation containing at least one drug, preferably a highly active drug, more preferably Tiotropium bromide or Tiotropium bromide monohydrate, and a lactose carrier. The process is characterized in that a thr... | 1. A process for preparing a dry powder inhalation formulation containing at least one drug and a lactose carrier, comprising the steps:
a) splitting the lactose carrier into a first, a second and a third portion, b) mixing the first and the second portion of the lactose carrier and the drug by
i) placing the first por... | The present invention relates to a simple, robust and effective process for preparing a dry powder inhalation formulation containing at least one drug, preferably a highly active drug, more preferably Tiotropium bromide or Tiotropium bromide monohydrate, and a lactose carrier. The process is characterized in that a thr... | 1,600 |
234 | 234 | 14,376,981 | 1,619 | Cosmetic and/or dermatological preparations based on a water-in-oil emulsion comprising at least two W/O emulsifiers which differ in their HLB value up to a maximum of 1 lead to sensorily acceptable preparations and at the same stable W/O emulsions. | 1-17. (canceled) 18. A cosmetic and/or dermatological preparation, wherein the preparation is based on a water-in-oil emulsion comprising at least two W/O emulsifiers which differ in their HLB value by at most 1. 19. The preparation of claim 18, wherein the at least two W/O emulsifiers differ in their HLB value by at m... | Cosmetic and/or dermatological preparations based on a water-in-oil emulsion comprising at least two W/O emulsifiers which differ in their HLB value up to a maximum of 1 lead to sensorily acceptable preparations and at the same stable W/O emulsions.1-17. (canceled) 18. A cosmetic and/or dermatological preparation, wher... | 1,600 |
235 | 235 | 14,264,983 | 1,611 | Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed o... | 1-83. (canceled) 84. A delivery system for topical administration of a locally active agent to the skin, the system comprising:
a body-surface contacting layer comprised of an adhesive hydrogel composition positioned on a backing layer, the adhesive hydrogel composition comprising: (i) a water-swellable, water-insolubl... | Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed o... | 1,600 |
236 | 236 | 14,746,758 | 1,611 | A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a w... | 1.-26. (canceled) 27. A method for preparing a system, the method comprising:
(i) providing a hydrogel comprising a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding or electrostatic bonding to the hydrophilic polymer, and optionally, an ... | A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a w... | 1,600 |
237 | 237 | 15,633,492 | 1,618 | A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is great... | 1. A solid drug unit comprising:
a drug in the form of a mini-tablet which is greater than 70% by weight the drug, with the balance being at least one excipient, wherein the mini-tablet is cylindrical with flat end faces, the length of the tablet exceeding its diameter so that the mini-tablet has an aspect ratio of gre... | A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is great... | 1,600 |
238 | 238 | 12,252,905 | 1,616 | Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated wit... | 1. A method of treating or preventing a neurodegenerative disease comprising administering cerium oxide nanoparticles having an average particle diameter size of about 2 nm to about 100 nm in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ(1-42), block Aβ... | Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated wit... | 1,600 |
239 | 239 | 13,462,466 | 1,628 | Novel compositions including bepotastine besilate and a corticosteroid are provided, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV. | 1-68. (canceled) 69. A method of treating at least one of rhinitis, mucosal inflammation associated with rhinitis, sinusitis, rhinosinusitis, and symptoms associated with rhinitis, mucosal inflammation associated with rhinitis, sinusitis, or rhinosinusitis in a patient in need of such treatment, the method comprising n... | Novel compositions including bepotastine besilate and a corticosteroid are provided, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.1-68. (canceled) 69. A method of treating at least one of rhinitis, mucosal inflammation associated... | 1,600 |
240 | 240 | 13,114,617 | 1,616 | The present invention is directed to a composition for the conditioning of a dental mineralized surface and/or a dental implant and/or for increasing the hydrophilicity of a dental implant having a metal containing surface. The composition comprises EDTA in a concentration of about 21-55% by weight and hydrogen peroxid... | 1. A conditioning composition comprising ethylenediaminetetraacetic acid (EDTA) at a concentration in the range of 21-55% by weight and hydrogen peroxide (H2O2) at a concentration of 2-4% by weight. 2. A conditioning composition according to claim 1, wherein the concentration of EDTA is in the range of 21-27% by weight... | The present invention is directed to a composition for the conditioning of a dental mineralized surface and/or a dental implant and/or for increasing the hydrophilicity of a dental implant having a metal containing surface. The composition comprises EDTA in a concentration of about 21-55% by weight and hydrogen peroxid... | 1,600 |
241 | 241 | 14,783,633 | 1,632 | Provided herein are, inter alia, are media compositions useful for culturing neural cells. In particular, the compositions provided herein mimic important physiological conditions in the living brain and sustain neural activity. The media compositions provided herein improve the efficiency of human neuron maturation an... | 1. A cell medium comprising:
(a) Sodium chloride at a concentration of between about 70 and about 150 mM; (b) a neuroactive inorganic salt at a concentration of between about 0.000001 and about 10 mM; (c) Glycine at a concentration of between about 0.0001 and about 0.05 mM; (d) L-alanine at a concentration of between a... | Provided herein are, inter alia, are media compositions useful for culturing neural cells. In particular, the compositions provided herein mimic important physiological conditions in the living brain and sustain neural activity. The media compositions provided herein improve the efficiency of human neuron maturation an... | 1,600 |
242 | 242 | 12,866,655 | 1,612 | This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form and a low dosage of fluoride and to methods of using such compositions. | 1. An oral care composition comprising:
a. an effective amount of a basic amino acid, in free or salt form; and b. a fluoride ion source which comprises not greater than 0.1% by weight of the composition. 2. The composition according claim 1 wherein the basic amino acid is arginine. 3. The composition according to clai... | This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form and a low dosage of fluoride and to methods of using such compositions.1. An oral care composition comprising:
a. an effective amount of a basic amino acid, in free or salt form; and b. a fluoride ... | 1,600 |
243 | 243 | 15,197,541 | 1,633 | The present invention provides silk proteins, as well as nucleic acids encoding these proteins. The present invention also provides recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the manufacture of personal care products... | 1-45. (canceled) 46. A silk polypeptide, wherein at least a portion of the polypeptide has a coiled coil structure, and wherein the polypeptide comprises an amino acid sequence which is at least 40% identical to any one or more of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:40, SEQ ID NO:41, SEQ ID ... | The present invention provides silk proteins, as well as nucleic acids encoding these proteins. The present invention also provides recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the manufacture of personal care products... | 1,600 |
244 | 244 | 14,523,242 | 1,615 | A method of making a personal care composition, such as dentifrice, using compacted rheology modifiers to control viscosity development. | 1. A method of producing a personal care composition comprising:
a) forming in a mix tank a premix having a lower viscosity than a packaged personal care composition; b) adding compacted rheology modifiers to the premix; c) transferring the premix from the mix tank; d) packaging the premix to produce a personal care co... | A method of making a personal care composition, such as dentifrice, using compacted rheology modifiers to control viscosity development.1. A method of producing a personal care composition comprising:
a) forming in a mix tank a premix having a lower viscosity than a packaged personal care composition; b) adding compact... | 1,600 |
245 | 245 | 12,813,564 | 1,612 | A composition in the form of an emulsion containing an aqueous phase, a fatty phase, a superabsorbent polymer, and an organic UV screening agent. Method for the treatment of a keratinous substance whereby the composition described is applied to the keratinous substance. | 1. A composition in the form of an emulsion comprising an aqueous phase, a fatty phase, a superabsorbent polymer, and an organic UV screening agent. 2. The composition according to claim 1, wherein the superabsorbent polymer is provided in the form of particles having a number-average diameter ranging from 10 μm to 100... | A composition in the form of an emulsion containing an aqueous phase, a fatty phase, a superabsorbent polymer, and an organic UV screening agent. Method for the treatment of a keratinous substance whereby the composition described is applied to the keratinous substance.1. A composition in the form of an emulsion compri... | 1,600 |
246 | 246 | 15,004,646 | 1,644 | Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method includes reducing antigen presenting cell function, such as cell trafficking to draining lymph nodes. In some instances, the method includes treating corneal transplant rejection in the subject. Aspects of... | 1. A method of reducing the occurrence of lymphangiogenesis in a corneal transplant subject, the method comprising administering to the subject an amount of an Ang-2 antagonist effective to reduce the occurrence of lymphangiogenesis in the subject. 2. The method according to claim 1, wherein the subject has a high risk... | Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method includes reducing antigen presenting cell function, such as cell trafficking to draining lymph nodes. In some instances, the method includes treating corneal transplant rejection in the subject. Aspects of... | 1,600 |
247 | 247 | 14,586,105 | 1,619 | Disclosed are oil-in-water (O/W) emulsions comprising (a) an aqueous dispersion of particles of at least one latex chosen from an acrylate latex, a polyurethane latex, or a silicone latex, (b) an oil phase, and (c) at least one surfactant, wherein the amount of the (a) aqueous dispersion of particles of at least one la... | 1. An oil-in-water emulsion comprising:
(a) an aqueous dispersion of particles of at least one latex chosen from an acrylate latex, a polyurethane latex, or a silicone latex, (b) an oil phase, and (c) at least one surfactant, wherein the amount of the (a) aqueous dispersion of particles of at least one latex chosen fro... | Disclosed are oil-in-water (O/W) emulsions comprising (a) an aqueous dispersion of particles of at least one latex chosen from an acrylate latex, a polyurethane latex, or a silicone latex, (b) an oil phase, and (c) at least one surfactant, wherein the amount of the (a) aqueous dispersion of particles of at least one la... | 1,600 |
248 | 248 | 15,147,198 | 1,617 | Disclosed are compositions and methods related to the use of kinase inhibitors in treating macular degeneration and/or retinal vein occlusion. | 1. An injectable composition, comprising a poorly water-soluble kinase inhibitor dissolved in a water-miscible organic solvent, wherein:
the concentration of the kinase inhibitor in the composition is at least 200 μg/mL; and the concentration of the kinase inhibitor in the composition is at least 100 times higher than ... | Disclosed are compositions and methods related to the use of kinase inhibitors in treating macular degeneration and/or retinal vein occlusion.1. An injectable composition, comprising a poorly water-soluble kinase inhibitor dissolved in a water-miscible organic solvent, wherein:
the concentration of the kinase inhibitor... | 1,600 |
249 | 249 | 13,515,853 | 1,641 | The invention relates to a substance determining apparatus and method for determining a substance within a fluid. Particles attach to the substance and bind to a binding surface ( 30 ), wherein a particle release curve being indicative of a release of bound particles from the binding surface ( 30 ) is determined, and a... | 1. A substance determining apparatus for determining a substance within a fluid (3), the substance determining apparatus (19) comprising:
particles (17) for being attached to the substance within the fluid (3), a binding surface (30) for binding the particles (17), if the particles (17) have been attached to the substa... | The invention relates to a substance determining apparatus and method for determining a substance within a fluid. Particles attach to the substance and bind to a binding surface ( 30 ), wherein a particle release curve being indicative of a release of bound particles from the binding surface ( 30 ) is determined, and a... | 1,600 |
250 | 250 | 14,960,960 | 1,612 | Disclosed herein are methods of promoting the aggregation and/or immune clearance of oral bacteria using oral care compositions comprising metal-amino acid complexes. | 1. A method of promoting the aggregation and/or immune clearance of oral bacteria, the method comprising the step of administering to the oral cavity of a person an oral care composition comprising a metal-amino acid complex;
wherein said person has demonstrated one or more of A. viscous, L. casei, S. oralis, V. parvul... | Disclosed herein are methods of promoting the aggregation and/or immune clearance of oral bacteria using oral care compositions comprising metal-amino acid complexes.1. A method of promoting the aggregation and/or immune clearance of oral bacteria, the method comprising the step of administering to the oral cavity of a... | 1,600 |
251 | 251 | 14,401,791 | 1,634 | The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sam... | 1-73. (canceled) 74. A method comprising:
exposing an aptamer to a first solid support, wherein the aptamer comprises a first tag and the first solid support comprises a first capture element, and wherein the first tag has affinity for the first capture element; allowing the first tag to associate with the first captur... | The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sam... | 1,600 |
252 | 252 | 13,859,811 | 1,644 | The production of soluble HLA class II molecules, as well as methods of using the soluble HLA class II molecules so produced, are described herein. | 1. A method of producing isolated, HLA class II trimolecular complexes, wherein the isolated, HLA class II trimolecular complexes comprise a soluble, glycosylated alpha chain, a soluble, glycosylated beta chain, and a non-covalently associated, endogenously produced peptide ligand, the method comprising the steps of:
i... | The production of soluble HLA class II molecules, as well as methods of using the soluble HLA class II molecules so produced, are described herein.1. A method of producing isolated, HLA class II trimolecular complexes, wherein the isolated, HLA class II trimolecular complexes comprise a soluble, glycosylated alpha chai... | 1,600 |
253 | 253 | 15,415,754 | 1,652 | Protein enriched micro-vesicles and methods of making and using the same are provided. Aspects of the methods include maintaining a cell having a membrane-associated protein comprising a first dimerization domain and a target protein having a second dimerization domain under conditions sufficient to produce a micro-ves... | 1.-34. (canceled) 35. A micro-vesicle comprising a membrane-associated protein comprising a first dimerization domain and a target protein comprising a second dimerization domain. 36. The micro-vesicle according to claim 35, wherein the membrane-associated protein and the target protein are present in a dimerized compl... | Protein enriched micro-vesicles and methods of making and using the same are provided. Aspects of the methods include maintaining a cell having a membrane-associated protein comprising a first dimerization domain and a target protein having a second dimerization domain under conditions sufficient to produce a micro-ves... | 1,600 |
254 | 254 | 14,174,433 | 1,613 | Disclosed is a method of providing cleanness to hair and/or scalp, for example, providing hair volume and/or providing less oiliness on hair and/or scalp, by applying a hair care composition comprising cationic surfactants, high melting point fatty compounds, metal pyrithione, and metal salts other than metal pyrithion... | 1. A method of providing cleanness to hair and/or scalp, comprising following steps:
(i) after shampooing hair, applying to the hair and/or scalp an effective amount of a hair care composition; and (ii) then rinsing the hair; wherein the hair care composition comprises by weight: (a) from about 0.1% to about 10% of a c... | Disclosed is a method of providing cleanness to hair and/or scalp, for example, providing hair volume and/or providing less oiliness on hair and/or scalp, by applying a hair care composition comprising cationic surfactants, high melting point fatty compounds, metal pyrithione, and metal salts other than metal pyrithion... | 1,600 |
255 | 255 | 14,342,889 | 1,627 | The invention provides a method for treating ALS or suppressing the disease progress thereof, or treating symptoms caused by ALS or suppressing the disease progress thereof by administering an agent containing, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, to... | 1.-4. (canceled) 5. A method for treating amyotrophic lateral sclerosis or suppressing the disease progress thereof, or treating symptoms caused by amyotrophic lateral sclerosis or suppressing the disease progress thereof, which comprises administering an effective amount of 3-methyl-1-phenyl-2-pyrazolin-5-one or a phy... | The invention provides a method for treating ALS or suppressing the disease progress thereof, or treating symptoms caused by ALS or suppressing the disease progress thereof by administering an agent containing, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, to... | 1,600 |
256 | 256 | 15,680,113 | 1,612 | The anesthetic chewing gum includes lidocaine HCL and prilocaine HCL as the anesthetic ingredients, as well as a chewing gum base. The anesthetic chewing gum may also include one or more sweeters, an anti-adherent, a lubricant, an opacifier, a glidant, a flavoring agent, and a flavor enhancer. | 1. An anesthetic chewing gum, comprising a combination of an analgesic component and a chewing gum base component:
the analgesic component consists of 2 mg lidocaine HCL and 2 mg prilocaine HCL; and the chewing gum base component comprises a chewing gum base. 2. The anesthetic chewing gum according to claim 1, wherein ... | The anesthetic chewing gum includes lidocaine HCL and prilocaine HCL as the anesthetic ingredients, as well as a chewing gum base. The anesthetic chewing gum may also include one or more sweeters, an anti-adherent, a lubricant, an opacifier, a glidant, a flavoring agent, and a flavor enhancer.1. An anesthetic chewing g... | 1,600 |
257 | 257 | 12,961,611 | 1,611 | A wipe that contains a fibrous web on which is coated an antimicrobial composition is provided. The composition includes a botanical oil derived from a plant (e.g., thymol, carvacrol, etc.). Because the botanical oil is volatile and tends to evaporate and lose efficacy during storage and prior to use, a protein is also... | 1. A wipe comprising a web that includes a plurality of fibers, wherein the web is coated with an antimicrobial composition, the antimicrobial composition comprising a botanical oil that is at least partially encapsulated by a film-forming protein, wherein the composition forms a discontinuous coating on at least a por... | A wipe that contains a fibrous web on which is coated an antimicrobial composition is provided. The composition includes a botanical oil derived from a plant (e.g., thymol, carvacrol, etc.). Because the botanical oil is volatile and tends to evaporate and lose efficacy during storage and prior to use, a protein is also... | 1,600 |
258 | 258 | 14,912,013 | 1,612 | An object of the present invention is to provide antimicrobial agents that do not contribute to the emergence of drug-resistant microorganisms, that present less side effects, and that can be combined with other medications while causing less adverse effects. The present invention provides antimicrobial agents containi... | 1-26. (canceled) 27. An antimicrobial agent comprising: at least one member selected from the group consisting of hydrogen atom (H); at least one hydrogen isotope selected from the group consisting of hydrogen atom (H); 1H, 2H, 3H, 4H, 5H, 6H and 7H; hydrogen molecule (H2); a metal hydride; hydrogen ion (H+); hydride i... | An object of the present invention is to provide antimicrobial agents that do not contribute to the emergence of drug-resistant microorganisms, that present less side effects, and that can be combined with other medications while causing less adverse effects. The present invention provides antimicrobial agents containi... | 1,600 |
259 | 259 | 14,755,185 | 1,639 | A method of treating mineral slurries to inhibit bacterial growth includes adding an effective amount of one or more of sodium N-methyldithiocarbamate or methylammonium monomethyldithiocarbamate to the mineral slurry to inhibit bacterial growth. | 1. In a method of treating a mineral slurry to inhibit bacterial growth by adding an effective amount of a biocide to the mineral slurry, the improvement comprising adding an effective amount of one or more of sodium or potassium N-methyldithiocarbamate and methylammonium monomethyldithiocarbamate to the mineral slurry... | A method of treating mineral slurries to inhibit bacterial growth includes adding an effective amount of one or more of sodium N-methyldithiocarbamate or methylammonium monomethyldithiocarbamate to the mineral slurry to inhibit bacterial growth.1. In a method of treating a mineral slurry to inhibit bacterial growth by ... | 1,600 |
260 | 260 | 13,446,594 | 1,628 | The present disclosure comprises a natural method of feed supplement to beef cattle, with a maize extract obtained from the nixtamalization process with a high content of ferulic acid and its salts, for a period of 30 days in the final phase of the feedlot. Use of this dietary supplementation enables an increase in car... | 1. A method for improving meat quality in beef cattle, which comprises administering a feed supplement comprising ferulic acid or a salt thereof in an amount from 100 to 250 mg. 2. The method according to claim 1, wherein said feed supplement comprises ferulic acid or a salt thereof in an amount from 150 to 200 mg. 3. ... | The present disclosure comprises a natural method of feed supplement to beef cattle, with a maize extract obtained from the nixtamalization process with a high content of ferulic acid and its salts, for a period of 30 days in the final phase of the feedlot. Use of this dietary supplementation enables an increase in car... | 1,600 |
261 | 261 | 15,492,528 | 1,619 | A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of... | 1. A method for increasing vasodilation comprising:
providing a mammal with an epidermal surface and a bloodstream having an initial systemic vasodilation of the bloodstream; providing a first medium comprising a nitrite compound; providing a second medium comprising at least two reducing agents; creating a mixture of ... | A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of... | 1,600 |
262 | 262 | 14,352,740 | 1,653 | The present invention provides, among other things methods of increasing cell density, viability and/or titer in a cell culture including steps of adding a composition comprising iron to the cell culture. | 1. A method of increasing cell density, viability, and/or titer in a cell culture medium comprising steps of:
(a) providing cells in a cell culture medium to start a cell culture process; and (b) adding a composition comprising iron to said cell culture medium during the cell culture process such that the concentration... | The present invention provides, among other things methods of increasing cell density, viability and/or titer in a cell culture including steps of adding a composition comprising iron to the cell culture.1. A method of increasing cell density, viability, and/or titer in a cell culture medium comprising steps of:
(a) pr... | 1,600 |
263 | 263 | 14,367,392 | 1,636 | Human skin tissue sample methods and models for identifying and screening test agents as effective for providing skin tone benefits, methods for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes contacting a cult... | 1. A screening method for identifying a test agent as effective for providing a skin tone benefit, comprising:
culturing a first human skin tissue sample, wherein the first human skin tissue sample comprises an epidermal layer and a dermal layer; contacting the human skin tissue sample with the test agent; generating a... | Human skin tissue sample methods and models for identifying and screening test agents as effective for providing skin tone benefits, methods for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes contacting a cult... | 1,600 |
264 | 264 | 14,345,695 | 1,627 | Methods and compositions for treating acute suicidality by administration of buprenorphine are disclosed herein. An exemplary method is effected by administering to a subject determined as having acute suicidality a first therapeutically effective amount of buprenorphine, or a pharmaceutically acceptable salt thereof, ... | 1-53. (canceled) 54. A method of treating acute suicidality in a subject in need thereof, the method being effected by administering to a subject determined as having acute suicidality a therapeutically effective amount of buprenorphine, or a pharmaceutically acceptable salt thereof, thereby treating said acute suicida... | Methods and compositions for treating acute suicidality by administration of buprenorphine are disclosed herein. An exemplary method is effected by administering to a subject determined as having acute suicidality a first therapeutically effective amount of buprenorphine, or a pharmaceutically acceptable salt thereof, ... | 1,600 |
265 | 265 | 14,363,538 | 1,653 | In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to TMJ implantation materials and implants (e.g., temporomandi bular joint (TMJ) methods of making TMJ implantation materials and implants, methods of formi... | 1. A temporomandibular joint (TMJ) disc, comprising: a TMJ scaffold structure having a plurality of holes in the scaffold structure. 2. The TMJ disc of claim 1, wherein the TMJ scaffold structure includes one or more populations of cells, wherein the population of cells is selected from the group consisting of:
a stem ... | In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to TMJ implantation materials and implants (e.g., temporomandi bular joint (TMJ) methods of making TMJ implantation materials and implants, methods of formi... | 1,600 |
266 | 266 | 14,775,829 | 1,617 | The present disclosure relates to controlling insect damage in a plant. In one embodiment, the methods include applying insecticide and at least one fertilizer in-furrow at planting. In particular examples, methods of controlling cutworms and/or rootworms in corn include applying tefluthrin and at least one pop-up fert... | 1. A method of controlling insect damage in a plant, the method comprising:
applying, at planting ±5 days, a
a pyrethroid insecticide and
a pop-up fertilizer. 2. The method of claim 1, wherein the pyrethroid insecticide includes at least one of permethrin, cypermethrin, fenvalerate, esfenvalerate, deltamethrin, cyhalot... | The present disclosure relates to controlling insect damage in a plant. In one embodiment, the methods include applying insecticide and at least one fertilizer in-furrow at planting. In particular examples, methods of controlling cutworms and/or rootworms in corn include applying tefluthrin and at least one pop-up fert... | 1,600 |
267 | 267 | 14,082,662 | 1,617 | An aqueous liquid composition comprising: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or hydrate; (b) a non-ionic surfactant; and (c) a preservative; wherein at least 90 percent of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically a... | 1. An aqueous liquid composition comprising: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; (b) a non-ionic surfactant; and (c) water; wherein the non-ionic surfactant is selected from the group consisting of copolymers of polyoxyethylene and polyoxy... | An aqueous liquid composition comprising: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or hydrate; (b) a non-ionic surfactant; and (c) a preservative; wherein at least 90 percent of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically a... | 1,600 |
268 | 268 | 12,682,582 | 1,623 | One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject. | 1-28. (canceled) 29. A method for maintaining or increasing growth of a foetal, infant, or child subject, the method comprising administering one or more complex lipids to a foetal, infant, or child subject in need thereof, wherein the one or more complex lipids comprises at least about 0.1% gangliosides w/w on a dry b... | One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.1-28. (canceled) 29. A method for maintaining or increasing growth of a foetal, infant, or child subj... | 1,600 |
269 | 269 | 14,172,604 | 1,612 | A method is provided of making a medicinal delivery system which satiates a craving in an individual when the medicinal delivery system is administered orally to the individual. A coating composition is applied on a saliva-soluble powder to establish a coated powder, the coating composition featuring an at least partia... | 1. A method of making a medicinal delivery system that delivers medicine which satiates a craving in an individual in need of craving relief when the medicinal delivery system is administered orally to the individual, comprising:
applying a coating composition on a saliva-soluble powder to establish a coated powder, th... | A method is provided of making a medicinal delivery system which satiates a craving in an individual when the medicinal delivery system is administered orally to the individual. A coating composition is applied on a saliva-soluble powder to establish a coated powder, the coating composition featuring an at least partia... | 1,600 |
270 | 270 | 13,412,051 | 1,632 | The present application relates to methods and compositions for treating diseased or damaged cardiac tissue comprising regenerative cells harvested from donor cardiac tissue. In one embodiment, regenerative cells are harvested from an allogeneic source and after administration result in increased viability and/or funct... | 1. A method for the reduction of teratoma formation following the delivery of non-self cells to a first subject, comprising:
delivering to a first subject a population of regenerative cells, wherein said regenerative cells are isolated from a tissue source harvested from a second subject, wherein said regenerative cell... | The present application relates to methods and compositions for treating diseased or damaged cardiac tissue comprising regenerative cells harvested from donor cardiac tissue. In one embodiment, regenerative cells are harvested from an allogeneic source and after administration result in increased viability and/or funct... | 1,600 |
271 | 271 | 13,139,809 | 1,631 | Exemplary embodiments of the present disclosure relate generally to methods, computer-accessible medium and systems for assembling haplotype and/or genotype sequences of at least one genome, which can be based upon, e.g., consistent layouts of short sequence reads and long-range genome related data. For example, a proc... | 1. A computer-accessible medium having stored thereon computer executable instructions for assembling at least one haplotype sequence or genotype sequence of at least one genome, wherein, when the executable instructions are executed by a processing arrangement, the processing arrangement is configured to perform at le... | Exemplary embodiments of the present disclosure relate generally to methods, computer-accessible medium and systems for assembling haplotype and/or genotype sequences of at least one genome, which can be based upon, e.g., consistent layouts of short sequence reads and long-range genome related data. For example, a proc... | 1,600 |
272 | 272 | 15,065,083 | 1,627 | The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention p... | 1-39. (canceled) 40. A method for treating a cancer in a patient that is a tumor that expresses β-catenin, comprising administering to the patient a specific inhibitor of CDK8/19. 41. A method for chemoprotecting a patient at risk for developing cancer, comprising administering to the patient a specific inhibitor of CD... | The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention p... | 1,600 |
273 | 273 | 13,701,619 | 1,619 | The present invention relates to a coating particle containing a nuclear particle covered with a coating layer, and in the coating particle, the coating layer is a layer containing hydroxyalkyl cellulose and a binder. | 1. A coating particle comprising a nuclear particle covered with a coating layer, wherein the coating layer is a layer comprising hydroxyalkyl cellulose and a binder. 2. The coating particle according to claim 1, wherein the binder is at least one selected from the group consisting of polyalkylene glycol, polyalkylene ... | The present invention relates to a coating particle containing a nuclear particle covered with a coating layer, and in the coating particle, the coating layer is a layer containing hydroxyalkyl cellulose and a binder.1. A coating particle comprising a nuclear particle covered with a coating layer, wherein the coating l... | 1,600 |
274 | 274 | 12,554,497 | 1,699 | The present invention is directed to a biomarker and kit for diagnosing, monitoring and/or staging Alzheimer's disease comprising redox-reactive autoantibodies. The present invention is also directed to a method for diagnosing, monitoring and/or staging Alzheimer's disease which comprises conducting a blood test using ... | 1. A method for diagnosing, monitoring and/or staging Alzheimer's disease which comprises conducting a blood test for redox-reactive autoantibodies. 2. A method in accordance with claim 1 wherein the autoantibodies are at least one of IgG, IgM, IgA, IgE, and IgD. 3. A method in accordance with claim 1 wherein the autoa... | The present invention is directed to a biomarker and kit for diagnosing, monitoring and/or staging Alzheimer's disease comprising redox-reactive autoantibodies. The present invention is also directed to a method for diagnosing, monitoring and/or staging Alzheimer's disease which comprises conducting a blood test using ... | 1,600 |
275 | 275 | 15,025,445 | 1,618 | An extruded water-soluble article includes a water-soluble polymer having an extrusion temperature of 90 to 150 C., a plasticizer, and one or more active agents in a total amount of 0.1% to 50% by weight of the article. Combining the active agent(s) with a plasticizer prior to melt-blending with the water-soluble polym... | 1. An extruded water-soluble article comprising:
a water-soluble, polymer having an extrusion temperature of 90 to 150° C.; a plasticizer; and one or more thermal active agents in a total amount of 0.1% to 50% by weight of the article, wherein the one or more thermal active agents are completely dissolvable/dispersible... | An extruded water-soluble article includes a water-soluble polymer having an extrusion temperature of 90 to 150 C., a plasticizer, and one or more active agents in a total amount of 0.1% to 50% by weight of the article. Combining the active agent(s) with a plasticizer prior to melt-blending with the water-soluble polym... | 1,600 |
276 | 276 | 14,353,833 | 1,613 | The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical p... | 1. A method of treating rhinitis comprising administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), to an animal in need thereof. 2. The method of claim 1, wherein the rhinitis is allergic rhinitis. 3. The method ... | The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical p... | 1,600 |
277 | 277 | 14,790,247 | 1,643 | Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies. | 1. A method for inducing or enhancing an immune response against an antigen in a subject comprising administering to the subject a monoclonal antibody which binds to human CD27, in an amount effective to induce or enhance an immune response against an antigen, wherein the antibody comprises a heavy chain variable regio... | Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.1. A method for inducing or enhancing an immune response against an antigen in a subject comprising administering to... | 1,600 |
278 | 278 | 14,423,062 | 1,634 | The present invention pertains to a method for isolation and purification of nucleic acids from a stabilized sample or portion or fraction thereof, wherein the sample stabilization involved the use of at least one formaldehyde releaser and wherein the isolation of the nucleic acids from the stabilized sample or portion... | 1. A method for isolating nucleic acids from a stabilized sample or portion or fraction thereof, wherein the sample stabilization involved the use of at least one formaldehyde releaser, comprising:
(a) lysing the stabilized sample or portion or fraction thereof in the presence of at least one cationic detergent to prov... | The present invention pertains to a method for isolation and purification of nucleic acids from a stabilized sample or portion or fraction thereof, wherein the sample stabilization involved the use of at least one formaldehyde releaser and wherein the isolation of the nucleic acids from the stabilized sample or portion... | 1,600 |
279 | 279 | 14,399,336 | 1,628 | Novel sterol derivatives, the preparation method thereof, pharmaceutical compositions containing them and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies. The treatment of glioblastoma multiforme, as well as of other cancers, such as lymphomas, neuroblastom... | 1-22. (canceled) 23. Compound of formula (I) having a 7beta-hydroxycholesterol basic structure
in which
A represents
an —(R1)n— group in which R1 is an amino acid residue bound by its
C-terminal end and n=1 or 2, each R1 being identical or different, in which the
N-terminal end of said amino acid can be sub... | Novel sterol derivatives, the preparation method thereof, pharmaceutical compositions containing them and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies. The treatment of glioblastoma multiforme, as well as of other cancers, such as lymphomas, neuroblastom... | 1,600 |
280 | 280 | 10,633,629 | 1,633 | Method and compositions for improving DNA polymerase and reverse transcriptase reactions are provided. Addition of anti-foam reagents to the reactions improves fluid handling, especially of small volumes and allows enhanced accuracy of optical detection, without substantially inhibiting enzymatic activity. | 1. A method for detecting a target nucleic acid in a sample, comprising the step of amplifying the target nucleic acid using a polymerase chain reaction, wherein said polymerase chain reaction is carried out in the presence of an effective amount of at least one anti-foam reagent that does not substantially inhibit the... | Method and compositions for improving DNA polymerase and reverse transcriptase reactions are provided. Addition of anti-foam reagents to the reactions improves fluid handling, especially of small volumes and allows enhanced accuracy of optical detection, without substantially inhibiting enzymatic activity.1. A method f... | 1,600 |
281 | 281 | 14,407,498 | 1,627 | The invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, together with pharmaceutically acceptable excipients, vehicle and/or carrier, as well as the pharmaceutical compositi... | 1. A pharmaceutical composition comprising a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, together with pharmaceutically acceptable excipients, vehicle and/or carrier, for use in the treatment and/or prevention of atrial fibrilla... | The invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, together with pharmaceutically acceptable excipients, vehicle and/or carrier, as well as the pharmaceutical compositi... | 1,600 |
282 | 282 | 15,279,939 | 1,643 | The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is ... | 1-21. (canceled) 22. A method for delivering an active ingredient selected from iloprost and salts thereof, to a patient in need thereof comprising the pulmonary administration of a pharmaceutical composition to the patient, wherein an amount of the composition administered comprises an effective single dose from 1.5 μ... | The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is ... | 1,600 |
283 | 283 | 13,265,756 | 1,699 | A bioperformance enhancing adjuvant of Formula (I) R 1 O[BO] n [AO] m R 2 where BO is butylene oxide; and each AO is independently propylene oxide or ethylene oxide; n is from 1 to 12; m is from 0 to 20; R 1 is optionally substituted C 4-20 alkyl or optionally substituted C 4-20 alkenyl; and R 2 is hydrogen or opt... | 1. (canceled) 2. A compound of formula (I)
R1O[BO]n[AO]mR2 (I)
where BO is butylene oxide; and each AO is independently propylene oxide or ethylene oxide; n is from 1 to 12; m is from 0 to 20; R1 is C4-20 alkyl or C4-20 alkenyl; and R2 is hydrogen or C1-3 alkyl; provided that the compound of formula (I) is not a com... | A bioperformance enhancing adjuvant of Formula (I) R 1 O[BO] n [AO] m R 2 where BO is butylene oxide; and each AO is independently propylene oxide or ethylene oxide; n is from 1 to 12; m is from 0 to 20; R 1 is optionally substituted C 4-20 alkyl or optionally substituted C 4-20 alkenyl; and R 2 is hydrogen or opt... | 1,600 |
284 | 284 | 15,685,257 | 1,644 | This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs. | 1-20. (canceled) 21. An isolated monoclonal antibody comprising at least one set of variable region amino acid sequences selected from the group consisting of:
a light chain variable region (LC-V) comprising the sequence of DIVMTQAAPSVPVTPGESVSISCRSX1KX2LLHRX3X4NTYLYWFLQRPGQSPQL LIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVY... | This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.1-20. (canceled) 21. An isola... | 1,600 |
285 | 285 | 14,678,749 | 1,699 | Described are methods of making organic compounds by metathesis chemistry. The methods of the invention are particularly useful for making industrially-important organic compounds beginning with starting compositions derived from renewable feedstocks, such as natural oils. The methods make use of a cross-metathesis ste... | 1-90. (canceled) 91. A method comprising:
providing (a) triglycerides and (b) short-chain olefins; cross-metathesizing the triglycerides and the short-chain olefins in the presence of a metathesis catalyst to provide cross-metathesis products comprising olefins and ester-functionalized alkenes; separating the olefins i... | Described are methods of making organic compounds by metathesis chemistry. The methods of the invention are particularly useful for making industrially-important organic compounds beginning with starting compositions derived from renewable feedstocks, such as natural oils. The methods make use of a cross-metathesis ste... | 1,600 |
286 | 286 | 15,641,451 | 1,617 | A method for the treatment of a local pigmentation disorder comprises applying to skin affected by the disorder a transdermal therapeutic system which comprises 4-n-butylresorcinol as an active ingredient. | 1. A method for the treatment of a local pigmentation disorder, wherein the method comprises applying to skin affected by the disorder a transdermal therapeutic system which comprises 4-n-butylresorcinol as an active ingredient. 2. The method of claim 1, wherein the local pigmentation disorder comprises local hyperpigm... | A method for the treatment of a local pigmentation disorder comprises applying to skin affected by the disorder a transdermal therapeutic system which comprises 4-n-butylresorcinol as an active ingredient.1. A method for the treatment of a local pigmentation disorder, wherein the method comprises applying to skin affec... | 1,600 |
287 | 287 | 13,515,925 | 1,656 | The present invention relates to a method for producing a hydrolysate of from lignocellulose-containing material, comprising pre-treatment with low temperature, hydrolysis and fermentation, wherein hydrolysis is performed by contacting the lignocellulose-containing material with an enzyme composition comprising at leas... | 1-15. (canceled) 16. A process for producing a hydrolysate of a lignocellulosic material comprising
a) subjecting the lignocellulosic material to a pretreatment at a temperature between 165° C. and 175° C., and b) subjecting the pretreated lignocellulosic material to the action of hydrolytic enzymes to produce a hydrol... | The present invention relates to a method for producing a hydrolysate of from lignocellulose-containing material, comprising pre-treatment with low temperature, hydrolysis and fermentation, wherein hydrolysis is performed by contacting the lignocellulose-containing material with an enzyme composition comprising at leas... | 1,600 |
288 | 288 | 15,106,279 | 1,612 | An oral care composition comprising: arginine in free or salt form; and zinc ions, wherein the zinc ions are present in the composition at a concentration of from 0.0001 mols/100 g to 0.0150 mols/100 g, based on the total weight of the composition. | 1. An oral care composition comprising:
a) arginine in free or salt form; and b) zinc ions, wherein the zinc ions are present in the composition at a concentration selected from the group consisting of from 0.0001 mols/100 g to 0.015 mols/100 g from 0.00025 mols/100 g, to 0.005 mols/100 g, from 0.0004 mols/100 g to 0.0... | An oral care composition comprising: arginine in free or salt form; and zinc ions, wherein the zinc ions are present in the composition at a concentration of from 0.0001 mols/100 g to 0.0150 mols/100 g, based on the total weight of the composition.1. An oral care composition comprising:
a) arginine in free or salt form... | 1,600 |
289 | 289 | 14,437,812 | 1,632 | Several embodiments disclosed herein relate generally to compositions of stem cells and methods of utilizing said compositions for repair, regeneration, and/or functional recovery of damaged tissue. In some embodiments the compositions comprise therapeutic populations of stem cells depleted of cells expressing one or m... | 1-18. (canceled) 19. A composition of therapeutic cells derived from donor cardiac tissue comprising a population of cells substantially depleted of cells expressing the CD90 cell marker. 19-50. (canceled) 51. The composition of claim 19, wherein said therapeutic population of cells is depleted of at least 90%, 95% or ... | Several embodiments disclosed herein relate generally to compositions of stem cells and methods of utilizing said compositions for repair, regeneration, and/or functional recovery of damaged tissue. In some embodiments the compositions comprise therapeutic populations of stem cells depleted of cells expressing one or m... | 1,600 |
290 | 290 | 14,443,862 | 1,639 | The invention relates to a hydrodispersion, comprising thickeners, waxes, and oils. The waxes and the overall preparation have specific melting ranges that ensure a pleasant, sensorily light profile and good care effects. | 1.-15. (canceled) 16. A hydrodispersion, wherein the hydrodispersion comprises, based on a total mass of the dispersion:
(a) water, (b) from 0.05% to 5% by weight of at least one thickener, (c) from 2% to 20% by weight of one or more waxes, at least one wax having a melting point Tonset below 30° C., and (d) from 0% to... | The invention relates to a hydrodispersion, comprising thickeners, waxes, and oils. The waxes and the overall preparation have specific melting ranges that ensure a pleasant, sensorily light profile and good care effects.1.-15. (canceled) 16. A hydrodispersion, wherein the hydrodispersion comprises, based on a total ma... | 1,600 |
291 | 291 | 14,685,510 | 1,636 | The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein,... | 1-57. (canceled) 58. A composition for cleaving a target nucleic acid sequence in a mammalian cell, the composition comprising a Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas system in the mammalian cell, wherein the Type II CRISPR/Cas system comprises:
a) a nucleic acid encoding a Cas9... | The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein,... | 1,600 |
292 | 292 | 14,556,510 | 1,611 | A controlled-release pharmaceutical composition including first and second groups of microparticles, each of the microparticles including a core including tamsulosin or pharmaceutically acceptable salts thereof, a controlled-release polymer coating layer formed on the core, and an enteric polymer outer layer formed on ... | 1-20. (canceled) 21. A method for controlling tamsulosin release so that upon oral administration, 30% or less of tamsulosin is released for 2 hours and the rest of tamsulosin is gradually released for 6 hours or longer, which comprises:
administering a pharmaceutical composition which comprises a first group of microp... | A controlled-release pharmaceutical composition including first and second groups of microparticles, each of the microparticles including a core including tamsulosin or pharmaceutically acceptable salts thereof, a controlled-release polymer coating layer formed on the core, and an enteric polymer outer layer formed on ... | 1,600 |
293 | 293 | 14,359,385 | 1,636 | An in vitro method for screening for candidate compounds for preventing and/or attenuating skin ageing, and/or hydrating skin, includes: a) contacting a test compound with a sample of papillary fibroblasts; b) measuring the expression of a gene selected from PDPN, CCRL1 and NTN1, in the papillary fibroblasts; and c) se... | 1. In vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin, and/or for hydrating the skin, comprising the following steps:
a. bringing at least one test compound in contact with a sample of papillary fibroblasts; b. measuring the expression of at least one gene selecte... | An in vitro method for screening for candidate compounds for preventing and/or attenuating skin ageing, and/or hydrating skin, includes: a) contacting a test compound with a sample of papillary fibroblasts; b) measuring the expression of a gene selected from PDPN, CCRL1 and NTN1, in the papillary fibroblasts; and c) se... | 1,600 |
294 | 294 | 13,882,566 | 1,632 | Provided herein are methods of inducing psychosis in animals using light-responsive opsins and methods of identifying or screening compounds that may be useful in treating psychosis. | 1. A non-human animal comprising a light-responsive opsin expressed on the cell membrane of a subset of layer V pyramidal neurons in the prefrontal cortex, wherein light activation of the opsin induces depolarization of the membrane and induces psychosis of the animal. 2. The animal of claim 1, wherein the subset of la... | Provided herein are methods of inducing psychosis in animals using light-responsive opsins and methods of identifying or screening compounds that may be useful in treating psychosis.1. A non-human animal comprising a light-responsive opsin expressed on the cell membrane of a subset of layer V pyramidal neurons in the p... | 1,600 |
295 | 295 | 15,531,254 | 1,633 | The invention encompasses methods for generating stable exosome formulations and encompasses stable exosome formulations. The exosome formulations encompass stable liquid exosome formulations and stable lyophilized exosome formulations. In some embodiments, the exosome formulations can be generated by ultrafiltration a... | 1. A stable lyophilized exosome formulation suitable for administration to a human comprising at least 106 exosomes, wherein the wherein the lyophilized exosomes maintain at least 90% of the levels of miR-210 RNA and miR-146A of the exosome formulation pre-lyophilization. 2. The stable lyophilized exosome formulation o... | The invention encompasses methods for generating stable exosome formulations and encompasses stable exosome formulations. The exosome formulations encompass stable liquid exosome formulations and stable lyophilized exosome formulations. In some embodiments, the exosome formulations can be generated by ultrafiltration a... | 1,600 |
296 | 296 | 15,575,076 | 1,699 | The invention discloses a process for the oxidation of limonene, comprising the reaction of limonene with hydrogen peroxide in the presence of a catalyst containing atoms and/or ions of at least one metal, selected from the group consisting of molybdenum, tungsten, scandium, vanadium, titanium, lanthanum, zirconium, pr... | 1. A process for the oxidation of limonene, comprising the reaction of limonene with hydrogen peroxide in the presence of a catalyst containing atoms and/or ions of at least one metal selected from the group consisting of molybdenum, tungsten, scandium, vanadium, titanium, lanthanum, zirconium, praseodymium, neodymium,... | The invention discloses a process for the oxidation of limonene, comprising the reaction of limonene with hydrogen peroxide in the presence of a catalyst containing atoms and/or ions of at least one metal, selected from the group consisting of molybdenum, tungsten, scandium, vanadium, titanium, lanthanum, zirconium, pr... | 1,600 |
297 | 297 | 14,881,714 | 1,611 | This invention relates to an improved crystallization process of hydrogenated castor oil structurant which results in (i) a dispersion having a high concentration of the structurant, and (ii) a crystal habit/form that results in a higher yield stress in the final product, imparting high stability, for a given amount st... | 1. A personal care composition comprising
a. from about 5% to about 25 wt % of an detersive surfactant; b. from about 1% to about 20% wt % of hydrogenated castor oil premix composition by weight of the personal care composition wherein the hydrogenated castor oil premix composition comprises:
i. from about 0.30% to abo... | This invention relates to an improved crystallization process of hydrogenated castor oil structurant which results in (i) a dispersion having a high concentration of the structurant, and (ii) a crystal habit/form that results in a higher yield stress in the final product, imparting high stability, for a given amount st... | 1,600 |
298 | 298 | 14,681,301 | 1,631 | Some embodiments are directed to an apparatus for monitoring patient orientation. A reusable sensor is configured to detect inclination angles of an anterior region of the patient. An elongated disposable attachment device is configured for removable attachment to both the sensor and the patient's anterior region such ... | 1. An apparatus for monitoring one or more conditions of a patient, comprising:
a reusable sensor configured to sense the one or more conditions of the patient; and a disposable attachment device configured for removable attachment to both the sensor and the patient's anterior region, the attachment device including: a... | Some embodiments are directed to an apparatus for monitoring patient orientation. A reusable sensor is configured to detect inclination angles of an anterior region of the patient. An elongated disposable attachment device is configured for removable attachment to both the sensor and the patient's anterior region such ... | 1,600 |
299 | 299 | 14,898,284 | 1,633 | Methods of making vaccinia viruses for gene-directed prodrug therapy are disclosed and their use in the treatment of disease is provided. In particular, the anti-tumor effects of vaccinia viruses that are modified to express a prodrug-activating enzyme are disclosed. | 1.-21. (canceled) 22. A vaccinia virus which is capable of expressing a glutamate carboxypeptidase within a cell. 23. The vaccinia virus according to claim 22, wherein the glutamate carboxypeptidase is CPG2 or a mutant, variant or homologue thereof. 24. The vaccinia virus according to claim 23, wherein the glutamate ca... | Methods of making vaccinia viruses for gene-directed prodrug therapy are disclosed and their use in the treatment of disease is provided. In particular, the anti-tumor effects of vaccinia viruses that are modified to express a prodrug-activating enzyme are disclosed.1.-21. (canceled) 22. A vaccinia virus which is capab... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.